1. Home
  2. GNLX vs ACOG Comparison

GNLX vs ACOG Comparison

Compare GNLX & ACOG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Genelux Corporation

GNLX

Genelux Corporation

HOLD

Current Price

$2.59

Market Cap

110.4M

Sector

Health Care

ML Signal

HOLD

Logo Alpha Cognition Inc.

ACOG

Alpha Cognition Inc.

HOLD

Current Price

$9.10

Market Cap

193.6M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
GNLX
ACOG
Founded
2001
2000
Country
United States
Canada
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
110.4M
193.6M
IPO Year
2022
2024

Fundamental Metrics

Financial Performance
Metric
GNLX
ACOG
Price
$2.59
$9.10
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
4
2
Target Price
$17.25
$16.00
AVG Volume (30 Days)
297.3K
162.7K
Earning Date
05-12-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
9.47
41.58
EPS
N/A
N/A
Revenue
$8,000.00
$10,220,275.00
Revenue This Year
N/A
$139.22
Revenue Next Year
N/A
$134.48
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.29
$4.50
52 Week High
$8.54
$10.14

Technical Indicators

Market Signals
Indicator
GNLX
ACOG
Relative Strength Index (RSI) 42.41 47.79
Support Level $2.51 $5.28
Resistance Level $2.95 $9.04
Average True Range (ATR) 0.15 0.55
MACD -0.01 -0.09
Stochastic Oscillator 25.89 3.57

Price Performance

Historical Comparison
GNLX
ACOG

About GNLX Genelux Corporation

Genelux Corp is a late-stage biopharmaceutical firm focused on developing oncolytic viral immunotherapies for cancer. Its pipeline includes clinical and preclinical candidates designed to target tumor cells and stimulate an immune response against tumor-specific antigens. The company is focused on the development of next-generation oncolytic viral immunotherapies that are designed to generate a personalized multi-prong attack to overwhelm a tumor's sophisticated defense mechanisms.

About ACOG Alpha Cognition Inc.

Alpha Cognition Inc is a biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimers disease, for which there are limited or no treatment options. The Companies current focus is on the commercial manufacturing and sales of ZUNVEYL oral tablet formulation. The Companies commercial development program for ZUNVEYL is focused on building a long-term care commercial team that can focus on providing key points of differentiation, exploiting key issues with existing Acetylcholinesterase inhibitors treatments, and seeking potential licensing partners for other additional indications and new formulations.

Share on Social Networks: